PLAU and Familial prostate cancer: Collectively, these results position uPA inhibition as a promising strategy to potentiate antitumor immunity and improve immunotherapy outcomes in prostate cancer, with the combination regimen demonstrating significantly enhanced efficacy compared to monotherapies.